Dr. Markman on the Era of Precision Medicine in Ovarian Cancer

Maurie Markman, MD
Published: Tuesday, Dec 19, 2017



Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the era of precision medicine in ovarian cancer.

Clinical trials have traditionally been the avenue in which efficacy of a novel agent is evaluated. Markman proposes that in the era of precision medicine, a new strategy must be developed to move drugs along in the regulatory process and prove their efficacy.

It is difficult to conduct randomized phase III trials in uncommon tumors such as ovarian cancer subtypes in a timely manner, says Markman, making the need for these novel strategies critical.
 


Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the era of precision medicine in ovarian cancer.

Clinical trials have traditionally been the avenue in which efficacy of a novel agent is evaluated. Markman proposes that in the era of precision medicine, a new strategy must be developed to move drugs along in the regulatory process and prove their efficacy.

It is difficult to conduct randomized phase III trials in uncommon tumors such as ovarian cancer subtypes in a timely manner, says Markman, making the need for these novel strategies critical.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x